Tecogen Inc. filings document the regulatory record for a Delaware operating company with common stock listed on NYSE American under TGEN. The company's Form 8-K reports furnish earnings releases, supplemental presentation materials, Regulation FD product communications, advisory agreement matters, and other events tied to its clean energy products and chiller applications.
Proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Other disclosures address related-person transactions, promissory note matters, capital structure, risk factors referenced in periodic reports, and governance controls around company agreements and public communications.
Tecogen Inc. (TGEN) reports that it has filed a Registration Statement on Form S-3 with the SEC to cover the reoffer and resale of 4,507,603 shares of common stock by certain selling stockholders. All shares were originally acquired in private placement transactions exempt from Securities Act registration.
Trusts associated with the Hatsopoulos family, holding 3,475,714 of these shares, entered into lock-up agreements that restrict most transfers for 182 calendar days starting on the date the SEC declares the S-3 effective, subject to limited exceptions. A form of the lock-up agreement is filed as Exhibit 99.1. Sales by selling stockholders may occur only after the S-3 becomes effective.
TECOGEN INC. (TGEN) has filed Post-Effective Amendment No. 3 to its previously effective registration statement to de-register all remaining unsold shares that were earlier registered for resale. The original Form S-3 registration covered 706,147 shares of common stock and was declared effective in 2016, later converted to Form S-1 by post-effective amendments in 2021 after the company voluntarily de-listed its common stock from The NASDAQ Stock Market and de-registered it under Section 12(b) of the Exchange Act. This amendment formally removes any unsold registered shares from registration in accordance with the company’s prior undertakings.
Tecogen Inc. reported weaker results for the quarter and six months ended June 30, 2026. For the first half of 2026, total revenues were $12.1 million, down from $14.6 million a year earlier, as Products revenue declined sharply while Services and Energy Production grew modestly. Net loss attributable to Tecogen widened to $4.27 million from $2.12 million, driven by lower gross profit and higher general and administrative and R&D expenses.
Cash and cash equivalents fell to $6.78 million from $12.43 million at December 31, 2025, reflecting $5.46 million of cash used in operating activities in the first half. Total assets were $31.6 million and total liabilities $14.1 million, leaving stockholders’ equity of $17.6 million. The Services segment, supported by acquired Aegis maintenance contracts, remains the largest revenue contributor.
Tecogen Inc. reported weaker results for the quarter and six months ended June 30, 2026. Quarterly revenues were $5.75 million, down 21.2% from 2025, driven by a 64.0% drop in Products revenue to $1.13 million, partly offset by Services growth of 10.3% to $4.38 million and Energy Production growth of 35.4% to $0.24 million. Gross profit was $2.17 million, with gross margin improving to 37.8% from 33.8% on higher Products segment margin.
Loss from operations widened to $2.15 million from $1.41 million, and net loss attributable to Tecogen increased to $2.15 million (loss of $0.07 per share) from $1.46 million (loss of $0.06). Adjusted EBITDA for the quarter was negative $1.68 million, compared with negative $1.16 million a year earlier.
For the first half of 2026, revenues were $12.08 million, down 17.1%, with Products revenue down 59.4% and Services up 9.8%. Net loss for the six months was $4.27 million (loss of $0.14 per share) versus $2.12 million in 2025. Cash and cash equivalents were $6.78 million at June 30, 2026, compared with $12.43 million at year-end. Management highlighted a non–data center backlog of approximately $8 million, expected additional orders of $2 million or more, and recent product demonstrations with large data centers representing more than 8 gigawatts of existing capacity.
Tecogen Inc. approved new equity awards and salary increases for its chief executive and other named executive officers. On June 26, 2026, the Board granted restricted stock and incentive stock options under the 2022 Stock Incentive Plan, including to CEO Abinand Rangesh, who received 174,081 shares of restricted stock and options on 26,041 shares. The awards vest in four equal annual installments and the options are exercisable at $5.17 per share. The Board also raised Mr. Rangesh’s annual base salary by 5% to $220,500, and increased base salaries for the other named officers by 3%, with new annual salaries ranging from $152,260 to $206,000.
Whiting John Kimball IV reported acquisition or exercise transactions in this Form 4 filing.
TECOGEN INC. reported that its General Counsel & Secretary, John Kimball Whiting IV, received a grant of 19,342 shares of Common Stock as a restricted stock award under the 2022 Stock Incentive Plan. The award vests in four equal installments of 25% per year. Following this grant, he directly holds 19,342 shares.
Lafaille Stephen reported acquisition or exercise transactions in this Form 4 filing.
TECOGEN INC. reported that VP of Business Development Stephen Lafaille received a grant of 29,013 shares of common stock as a compensation award. The shares were granted at no cash cost to him and are structured as a Restricted Stock Award under the company’s 2022 Stock Incentive Plan.
The award vests in stages, with 25% of the shares vesting each year, which is designed to encourage long-term alignment with the company’s performance and retention over several years. Following this grant, Lafaille holds 29,013 common shares directly, with no derivative securities reported in this filing.
TECOGEN INC. Chief Accounting Officer Roger P. Deschenes reported an acquisition of 29,013 shares of common stock through a restricted stock award. The award was granted at no cash cost per share and represents his entire directly held position after the transaction. The grant vests in equal 25% installments each year under the company’s 2022 Stock Incentive Plan, meaning the shares become fully owned over four years as service conditions are met.
Tecogen Inc. reported that COO and President Robert Panora received new equity awards. He acquired 9,671 shares of Common Stock as a restricted stock award under the 2022 Stock Incentive Plan, with the grant made at no cash cost to him.
Panora was also granted stock options covering 26,041 shares of Common Stock at an exercise price of $5.17 per share. The options are incentive stock options under the 2022 Stock Incentive Plan, vesting 25% per year and expiring on June 26, 2036. After these grants, his reported direct holdings from this award are 9,671 shares and 26,041 options.
Tecogen Inc. director and CEO Rangesh Abinand received new equity awards in the form of common stock and stock options. He was granted 174,081 shares of common stock as a restricted stock award at no cash cost, vesting 25% per year under the 2022 Stock Incentive Plan. He also received an incentive stock option covering 26,041 shares of common stock at an exercise price of $5.17 per share, which also vests 25% per year and is exercisable until June 26, 2036. Following these grants, his reported direct holdings are 174,081 common shares and options on 26,041 shares.